Literature DB >> 15053061

Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.

N Fersis1, B Smyczek-Gargya, S Armeanu, E Gagulic, L Pantic, K Relakis, M Friedrich, D Wallwiener.   

Abstract

PURPOSE: Angiogenesis has been proposed as a possible target for anticancer treatment, either by inhibition of the production of angiogenic factors or by inhibition of endothelial cell proliferation. The impact of preoperative chemoendocrine therapy is unknown in the regulation of angiogenic factors, but recent reports suggest that anticancer drugs have antiangiogenic activity.
METHODS: The expression of two angiogenic factors VEGF and Angiopoetin-1 were quantified at different concentrations of doxorubicin, docetaxel, tamoxifen, exemestane and letrozol on MCF-7 and T47D cells.
RESULTS: Low-drug concentrations led to increased VEGF-A gene transcription whereas high (10-fold increased) drug concentrations suppressed gene expression. A similar cell reaction was observed for VEGF protein with a smaller variety in the extent of modulation. Incubation of MCF-7 cells to different drugs showed a similar dose-dependent modulation of Angiopoietin-1 gene expression with enhancement at low-drug concentrations.
CONCLUSION: Treatment of breast cancer cells following a preoperative protocol showed a dose-dependent expression of VEGF and Angiopoetin-1. Only high-drug concentrations were followed by a decreased secretion of both factors whereas low concentrations induced up-regulation of VEGF and Angiopoietin 1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053061

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  Metronomic chemotherapy: changing the paradigm that more is better.

Authors:  O G Scharovsky; L E Mainetti; V R Rozados
Journal:  Curr Oncol       Date:  2009-03       Impact factor: 3.677

2.  Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.

Authors:  Hachidai Hirakawa; Yoshihito Yokoyama; Hidemi Yoshida; Hideki Mizunuma
Journal:  J Ovarian Res       Date:  2014-01-10       Impact factor: 4.234

3.  Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process.

Authors:  Alicia González-González; Alicia González; Noemi Rueda; Carolina Alonso-González; Javier Menéndez Menéndez; Carlos Martínez-Campa; Stefania Mitola; Samuel Cos
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.